1217769-79-3

Basic information

• Product Name: (S)-Casodex-d4
• Synonyms: (2S)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl-d4)sulfonyl]-2-hydroxy-2-methylpropanamide;(S)-Bicalutamide-d4;(S)-Casodex-d4
• CAS NO: 1217769-79-3
• Molecular Formula: C18H14F4N2O4S
• Molecular Weight: 430.3733728
• Product Categories: Chiral Reagents;Intermediates & Fine Chemicals;Isotope Labeled Compounds;Pharmaceuticals;Sulfur & Selenium Compounds;Isotope Labelled Compounds
• Mol File: 1217769-79-3.mol
• Article Data: 0

Chemical Properties

• Melting Point: 175-179°C
• Appearance: /
• Storage Temp.: -20°C Freezer
• Solubility: Acetone, Ethyl Acetate
• CAS DataBase Reference: (S)-Casodex-d4(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-Casodex-d4(1217769-79-3)
• EPA Substance Registry System: (S)-Casodex-d4(1217769-79-3)

Safety Data

• Hazardous Substances Data: 1217769-79-3(Hazardous Substances Data)

Usage

Description

(S)-Casodex-d4, also known as bicalutamide d4, is a deuterated form of the antiandrogen drug bicalutamide. It is an off-white crystalline solid with chemical properties that make it useful in various applications, particularly in the pharmaceutical industry. As a deuterated compound, (S)-Casodex-d4 offers enhanced stability and improved analytical performance in research and development.

Uses

Used in Pharmaceutical Industry:
(S)-Casodex-d4 is used as an antiandrogen for the treatment of prostate cancer. It works by blocking the effects of androgens, which are hormones that stimulate the growth of prostate cancer cells. This helps in slowing down the progression of the disease and improving the quality of life for patients.
(S)-Casodex-d4 is also used as an antineoplastic (hormonal) agent, which means it is involved in the treatment of cancer by targeting specific hormonal pathways. Its deuterated nature provides advantages in terms of stability and analytical performance, making it a valuable tool in the development of new cancer therapies.
Additionally, (S)-Casodex-d4 can be used in drug delivery systems to improve the bioavailability and therapeutic outcomes of antiandrogen treatments. By incorporating (S)-Casodex-d4 into novel drug delivery platforms, researchers can enhance the effectiveness of these treatments and potentially overcome resistance issues in cancer patients.